Hidenori Nonaka, Group Manager of the Non-Clinical Research Group, Division of Regenerative Medicine Research & Development at Rohto Pharmaceutical, focuses on the development of cell therapy products using allogenic mesenchymal stem cells (MSC). After joining Rohto in 2014, he’s been playing a major role in developing ADR-001, one of Rohto’s MSC products which has been under clinical investigations for multiple indications including liver cirrhosis and COVID-19.